Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- MHLW Panel Sets Topics for PMD Act Amendment; Pediatrics, Drug Loss on Agenda
April 19, 2024
- Japan Govt Sued for Lack of Information on COVID Vaccine Risks
April 18, 2024
- MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
- PMDA Stepping Up Generic Compliance Inspections from August Approvals
April 16, 2024
- 14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
April 15, 2024
- Japan to Discuss Orphan Designation for Cannabidiol, 2 More Drugs
April 15, 2024
- Japan Might Approve 1st Eylea Biosimilar by June, but Not AMD Use
April 15, 2024
- Japan Will Persistently Urge China to Release Detained Astellas Employee: Govt
April 12, 2024
- Alexion’s Voydeya Marks 1st Application of “Early Launch Premium,” but Rate Fully Axed
April 11, 2024
- Lagevrio to Get 8.2% Price Cut in July, 2.7% for Kerendia: CEA
April 11, 2024
- Average PMP Rate Hits Record Low at 1.2% in FY2024: MHLW
April 11, 2024
- Nobelpharma, Argenx Challenged Initial Pricing for New Meds; Claims Partially Accepted
April 11, 2024
- Argenx’s gMG Therapy Vyvdura OK’ed for Self-Injection
April 11, 2024
- Label Revision Ordered for 3 Beta Blockers to Delete Contraindication in Pregnant Women
April 10, 2024
- Fanconi Syndrome Found in Majority of Health Damages Tied to Beni-Koji Supplements
April 10, 2024
- LDP Healthcare Clique Urges Rethink of Rationale for Off-Year Drug Price Revisions
April 10, 2024
- Lawmakers’ Group on Pollen Allergy to Compile Opinion Paper towards Honebuto
April 9, 2024
- LDP Generic League to Soon Draw Up Proposal towards Honebuto Policy
April 9, 2024
- Japan Requests Self-Inspections for All Generic Firms; Report Due by October-End
April 9, 2024
- MOF Panel Begins Debate for FY2025 Budget Proposal, Mulls Spending Target
April 5, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…